StemCell Therapy

Zacks Investment Research cut shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports.

According to Zacks, Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The companys bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

MRUS has been the subject of a number of other reports. ValuEngine upgraded Merus from a sell rating to a hold rating in a research note on Thursday. BidaskClub upgraded Merus from a hold rating to a buy rating in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the companys stock. The company presently has an average rating of Buy and an average price target of $23.43.

Shares of MRUS traded up $0.33 during trading hours on Friday, hitting $15.99. The stock had a trading volume of 102,700 shares, compared to its average volume of 91,051. The companys fifty day simple moving average is $17.16 and its 200 day simple moving average is $15.58. The firm has a market cap of $335.80 million, a P/E ratio of -8.69 and a beta of 0.24. Merus has a 12-month low of $11.00 and a 12-month high of $20.95.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Monday, August 19th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks consensus estimate of ($0.54) by ($0.03). The firm had revenue of $6.27 million during the quarter, compared to analyst estimates of $8.62 million. Merus had a negative return on equity of 41.68% and a negative net margin of 104.10%. As a group, sell-side analysts expect that Merus will post -1.74 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Artal Group S.A. grew its stake in Merus by 16.7% in the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology companys stock worth $5,128,000 after purchasing an additional 50,000 shares in the last quarter. Morgan Stanley lifted its holdings in Merus by 3.1% in the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology companys stock worth $1,359,000 after acquiring an additional 2,788 shares during the last quarter. Athanor Capital LP bought a new position in Merus in the second quarter worth about $334,000. Finally, JPMorgan Chase & Co. lifted its holdings in Merus by 63.5% in the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology companys stock worth $123,000 after acquiring an additional 3,389 shares during the last quarter. Institutional investors and hedge funds own 52.00% of the companys stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

See the original post:
Merus (NASDAQ:MRUS) Stock Rating Lowered by Zacks Investment Research - Polson News

This entry was posted on November 3, 2019 at 12:45 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |